|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Research and development expenses, net | |||||
| Marketing expenses | |||||
| General and administrative expenses | |||||
| Merger transaction costs | |||||
| Total operating expenses | |||||
| Other expenses (expenses for merger with NLS) | |||||
| Operating loss | |||||
| Other income due to the termination of EF License Agreement | |||||
| Financing income | |||||
| Financing expenses related to convertible instruments | |||||
| Other financing expenses | |||||
| Interest expense | |||||
| Interest on related party loans | |||||
| Net financing expenses | |||||
| Loss before taxes on income | |||||
| Total Loss | |||||
| Defined pension plan adjustments | |||||
| Deemed dividend | |||||
| Adjustments arising from translating financial statements from functional currency to presentation currency | |||||
| Total other comprehensive loss | |||||
| Total comprehensive loss | |||||
| Net loss attributable to common shareholders | |||||
| Basic loss per share (in USD) (in Dollars per share) | |||||
| Diluted loss per share (in Dollars per share) | |||||
| Weighted average common shares used in computing basic net loss per common share (in Shares) | |||||
| Weighted average common shares used in computing diluted net loss per common share (in Shares) | |||||
Loading...